|
|
 |
 |
|
 |
 |
Efficacy
Kogenate® and Kogenate® FS have a long history of efficacy across all patient groups.1-3
- Demonstrated excellent hemostatic response in previously untreated patients (PUPs) and minimally treated patients (MTPs).1, 2
- Demonstrated excellent hemostatic response in previously treated patients (PTPs).3
- In prospective controlled clinical trials, 89% of bleeds in PUPs and MTPs and 93% of the bleeds in PTPs were successfully treated with only 1 or 2 infusions.1-3
- Low incidence of inhibitor formation in PTPs and PUPS/MTPs.2-6
| Number of patients with severe hemophilia A |
61* |
71** |
| De novo inhibitor development |
16% |
None |
| Bleeds treated with 1 or 2 infusions |
89% |
93% |
* Long-term, prospective clinical trials conducted in 61 patients with severe hemophilia A (<2% FVIII activity), over 45 months in North America (NA: n=31) and Europe (EU: n=30). Total number of bleeding episodes in NA and EU combined were 1,173.
** Long-term, open-label, prospective clinical trials conducted in 71 patients with severe hemophilia A (<2% residual FVIII activity), over 18 months in North America (NA: n=38) and 24 months in Europe (EU: n=33). Total number of bleeding episodes in NA and EU combined were 5,673.
Remember, your doctor or healthcare provider is the single best source of information regarding you and your health. Please consult your doctor if you have any questions about your health, your symptoms, or your therapy.
|
1 Data on File, Bayer HealthCare, MRR 1603.
|
|
2 Data on File, Bayer HealthCare, PH 31866.
|
|
3 Abshire TC, Brackmann HH, Scharrer I, et al. Sucrose formulated recombinant human antihemophilic Factor VIII is safe and efficacious for treatment of hemophilia A in home therapy. Thromb Haemost. 2000; 83(6):811-816.
|
|
4 Ljung RCR. Annotation: Can haemophilic arthropathy be prevented? Br J Haematol 1998;101:215-9.
|
|
5 Ljung RCR. Prophylactic infusion regimens iun the management of hemophiolia. Thromb Haemost 1999;82(2):525-30.
|
|
6 Blanchette VS, McCready M, et al. A survey of factor prophylaxis in boys with haemophilia followed in North American haemophilia treatment centres. Haemophilia 2003;9(Suppl 1):19-26.
|
|
|
|
|
|
|
